Cargando…

Role of monoclonal antibody drugs in the treatment of COVID-19

Currently clinicians all around the world are experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical presentation of this pathology includes fever, dry cough, fatigue and acute respiratory distress syndrome that can lead to death infected patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ucciferri, Claudio, Vecchiet, Jacopo, Falasca, Katia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Opinion Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559676/ https://www.ncbi.nlm.nih.gov/pubmed/33083387 http://dx.doi.org/10.12998/wjcc.v8.i19.4280

Ejemplares similares

Are monoclonal antibodies effective in patients with severe obesity in SARS‐CoV‐2 infected?
por: Ucciferri, Claudio, et al.
Publicado: (2023)

Use of Hematopoietic Growth Factor in the Management of Hematological Side Effects Associated to Antiviral Treatment for Hcv Hepatitis
por: Mancino, Paola, et al.
Publicado: (2010)

Molnupiravir as an Early Treatment for COVID-19: A Real Life Study
por: Pontolillo, Michela, et al.
Publicado: (2022)

Pidotimod in Paucisymptomatic SARS-CoV2 Infected Patients
por: Ucciferri, Claudio, et al.
Publicado: (2020)

Cardiac Toxicity Associated with HCV Direct Antiviral Agents
por: Ucciferri, Claudio, et al.
Publicado: (2018)

Improving BNT162b2 mRNA Vaccine Tolerability without Efficacy Loss by Pidotimod Supplementation
por: Ucciferri, Claudio, et al.
Publicado: (2022)

Hypertension and microalbuminuria in HIV infected patients: beneficial effects of the treatment with telmisartan
por: Ucciferri, Claudio, et al.
Publicado: (2010)

New Therapeutic Options in Mild Moderate COVID-19 Outpatients
por: Ucciferri, Claudio, et al.
Publicado: (2022)

Cystatin C and cardiovascular risk in HIV infected patients
por: Falasca, Katia, et al.
Publicado: (2010)

Long term effect of telmisartan in HIV-positive male patients with high blood pressure
por: Ucciferri, Claudio, et al.
Publicado: (2015)

Long term effect of switching to darunavir/ritonavir in HIV infected patients previously on protease inhibitor therapy
por: Ucciferri, Claudio, et al.
Publicado: (2016)

Canakinumab in a subgroup of patients with COVID-19
por: Ucciferri, Claudio, et al.
Publicado: (2020)

Parameters associated with diagnosis of COVID‐19 in emergency department
por: Ucciferri, Claudio, et al.
Publicado: (2021)

Risk Factors Associated with Poor Outcome in Patients with Infective Endocarditis: An Italian Single-Center Experience
por: Ucciferri, Claudio, et al.
Publicado: (2022)

Effect of Probiotic Supplement on Cytokine Levels in HIV-Infected Individuals: A Preliminary Study
por: Falasca, Katia, et al.
Publicado: (2015)

Atypical Sites of Lymphadenopathy after Anti-COVID-19 Vaccine: Ultrasound Features
por: Cocco, Giulio, et al.
Publicado: (2022)

Efficacy of canakinumab in mild or severe COVID‐19 pneumonia
por: Katia, Falasca, et al.
Publicado: (2021)

The impact of homocysteine, B(12), and D vitamins levels on functional neurocognitive performance in HIV-positive subjects
por: Falasca, Katia, et al.
Publicado: (2019)

Predictive factors and prevalence of microalbuminuria in HIV-infected patients: a cross-sectional analysis
por: Falasca, Katia, et al.
Publicado: (2017)

Duration of COVID-19: Data from an Italian Cohort and Potential Role for Steroids
por: D’Ardes, Damiano, et al.
Publicado: (2020)

Early detection of pleuro‐pulmonary tuberculosis by bedside lung ultrasound: A case report and review of literature
por: Cocco, Giulio, et al.
Publicado: (2022)

Effects of Probiotic Mixture Supplementation on the Immune Response to the 13-Valent Pneumococcal Conjugate Vaccine in People Living with HIV
por: Reale, Marcella, et al.
Publicado: (2021)

Predictive Value of Echocardiographic Pulmonary to Left Atrial Ratio for In-Hospital Death in Patients with COVID-19
por: Renda, Giulia, et al.
Publicado: (2023)

Approach to COVID-19 in older adults and indications for improving the outcomes
por: Tana, Claudio, et al.
Publicado: (2023)

Air and surface measurements of SARS-CoV-2 inside a bus during normal operation
por: Di Carlo, Piero, et al.
Publicado: (2020)

Leishmania tarentolae: an alternative approach to the production of monoclonal antibodies to treat emerging viral infections
por: Jones, Joshua D
Publicado: (2015)

Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
por: Cummings, Jeffrey
Publicado: (2023)

Iron Dyshomeostasis in COVID-19: Biomarkers Reveal a Functional Link to 5-Lipoxygenase Activation
por: Dufrusine, Beatrice, et al.
Publicado: (2022)

Clinical and Regulatory Challenges and Opportunities for Monoclonal Antibodies in Low- and Middle-Income Countries: Lessons from COVID-19 and Beyond
por: Gieber, Lisa, et al.
Publicado: (2023)

The Relevance of Monoclonal Antibodies in the Treatment of COVID-19
por: Torrente-López, Anabel, et al.
Publicado: (2021)

Quinacrine, an Old Drug with Potentially usefull in the Treatment for COVID-19
por: PINEDA, BENJAMIN
Publicado: (2021)

Trends in the Development and Approval of Monoclonal Antibodies for Viral Infections
por: Reichert, Janice M.
Publicado: (2012)

Neutralizing monoclonal antibodies for treatment of COVID-19
por: Taylor, Peter C., et al.
Publicado: (2021)

Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic
por: Dunlop, Adrian, et al.
Publicado: (2020)

Neutralizing monoclonal antibodies for COVID-19 treatment and prevention
por: Jaworski, Juan Pablo
Publicado: (2021)

Monoclonal antibodies as treatment for COVID-19
por: Medina Gamero, A., et al.
Publicado: (2022)

Advances in preclinical evaluation of experimental antibody-drug conjugates
por: Lyons, Scott K., et al.
Publicado: (2021)

Application of Monoclonal Antibody Drugs in Treatment of COVID-19: a Review
por: Kirillova, Aleksandra, et al.
Publicado: (2022)

The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates
por: Escrivá-de-Romaní, Santiago, et al.
Publicado: (2023)

Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs
por: Nwabufo, Chukwunonso K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_arbggp5f6rnved40mpram7fcqb